#MSD and #DaiichiSankyo's regulatory efforts for their antibody-drug conjugates (#ADCs) for cancer have stuttered again, with a withdrawn filing for #lungcancer candidate ifinatamab deruxtecan (I-DXd) in the US.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#MSD and #DaiichiSankyo's regulatory efforts for their antibody-drug conjugates (#ADCs) for cancer have stuttered again, with a withdrawn filing for #lungcancer candidate ifinatamab deruxtecan (I-DXd) in the US.
@4040rec.bsky.social@pharmaphorum.bsky.socialAround 1,000 patients in #England with a form of incurable #breastcancer will be able to get access to #AstraZeneca and #DaiichiSankyo's life-extending drug, #Enhertu, via the #NHS from today.